2021 ICD-10-CM Diagnosis Code C90.0

Multiple myeloma

    2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
  • C90.0 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
  • The 2021 edition of ICD-10-CM C90.0 became effective on October 1, 2020.
  • This is the American ICD-10-CM version of C90.0 - other international versions of ICD-10 C90.0 may differ.
Applicable To
  • Kahler's disease
  • Medullary plasmacytoma
  • Myelomatosis
  • Plasma cell myeloma
Type 1 Excludes
Type 1 Excludes Help
A type 1 excludes note is a pure excludes. It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as C90.0. A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
  • solitary myeloma (
    ICD-10-CM Diagnosis Code C90.3

    Solitary plasmacytoma

      2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
    Applicable To
    • Localized malignant plasma cell tumor NOS
    • Plasmacytoma NOS
    • Solitary myeloma
    C90.3-
    )
  • solitary plasmactyoma (
    ICD-10-CM Diagnosis Code C90.3

    Solitary plasmacytoma

      2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
    Applicable To
    • Localized malignant plasma cell tumor NOS
    • Plasmacytoma NOS
    • Solitary myeloma
    C90.3-
    )
The following code(s) above C90.0 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to C90.0:
  • C00-D49
    2021 ICD-10-CM Range C00-D49

    Neoplasms

    Note
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
    Neoplasms
  • C81-C96
    2021 ICD-10-CM Range C81-C96

    Malignant neoplasms of lymphoid, hematopoietic and related tissue

    Type 2 Excludes
    • Kaposi's sarcoma of lymph nodes (C46.3)
    • secondary and unspecified neoplasm of lymph nodes (C77.-)
    • secondary neoplasm of bone marrow (C79.52)
    • secondary neoplasm of spleen (C78.89)
    Malignant neoplasms of lymphoid, hematopoietic and related tissue
  • C90
    ICD-10-CM Diagnosis Code C90

    Multiple myeloma and malignant plasma cell neoplasms

      2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
    Type 1 Excludes
    • personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues (Z85.79)
    Multiple myeloma and malignant plasma cell neoplasms
Clinical Information
  • A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (who, 2001)
  • A malignancy of mature plasma cells engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess bence-jones proteins (free monoclonal immunoglobulin light chains) in the urine, skeletal destruction, bone pain, and fractures. Other features include anemia; hypercalcemia; and renal insufficiency.
  • A malignant neoplasm of the bone marrow composed of plasma cells.
  • A type of cancer that begins in plasma cells (white blood cells that produce antibodies).
  • Malignant neoplasm of plasma cells usually arising in the bone marrow and manifested by skeletal destruction, bone pain, and the presence of anomalous immunoglobulins.
  • Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bone.no one knows the exact causes of multiple myeloma, but it is more common in older people and african-americans. Early symptoms may include
    • bone pain, often in the back or ribs
    • broken bones
    • weakness or fatigue
    • weight loss
    • repeated infections
    myeloma is hard to cure. Treatment may help control symptoms and complications. Options include chemotherapy, stem cell transplantation and radiation. nih: national cancer institute
Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
Code annotations containing back-references to C90.0:
  • Code Also: D47.02
    ICD-10-CM Diagnosis Code D47.02

    Systemic mastocytosis

      2018 - New Code 2019 2020 2021 Billable/Specific Code
    Applicable To
    • Indolent systemic mastocytosis
    • Isolated bone marrow mastocytosis
    • Smoldering systemic mastocytosis
    • Systemic mastocytosis, with an associated hematological non-mast cell lineage disease (SM-AHNMD)
    Code Also
    • , if applicable, any associated hematological non-mast cell lineage disease, such as:
    • acute myeloid leukemia (C92.6-, C92.A-)
    • chronic myelomonocytic leukemia (C93.1-)
    • essential thrombocytosis (D47.3)
    • hypereosinophilic syndrome (D72.1)
    • myelodysplastic syndrome (D46.9)
    • myeloproliferative syndrome (D47.1)
    • non-Hodgkin lymphoma (C82-C85)
    • plasma cell myeloma (C90.0-)
    • polycythemia vera (D45)
    Type 1 Excludes
    • aggressive systemic mastocytosis (C96.21)
    • mast cell leukemia (C94.3-)
  • Code First: N08
    , N16
    , M36.1
    ICD-10-CM Diagnosis Code N08

    Glomerular disorders in diseases classified elsewhere

      2016 2017 2018 2019 2020 2021 Billable/Specific Code Manifestation Code
    Applicable To
    • Glomerulonephritis
    • Nephritis
    • Nephropathy
    Code First
    Type 1 Excludes
    • glomerulonephritis, nephritis and nephropathy (in):
    • antiglomerular basement membrane disease (M31.0)
    • diabetes (E08-E13 with .21)
    • gonococcal (A54.21)
    • Goodpasture's syndrome (M31.0)
    • hemolytic-uremic syndrome (D59.3)
    • lupus (M32.14)
    • mumps (B26.83)
    • syphilis (A52.75)
    • systemic lupus erythematosus (M32.14)
    • Wegener's granulomatosis (M31.31)
    • pyelonephritis in diseases classified elsewhere (N16)
    • renal tubulo-interstitial disorders classified elsewhere (N16)
    ICD-10-CM Diagnosis Code N16

    Renal tubulo-interstitial disorders in diseases classified elsewhere

      2016 2017 2018 2019 2020 2021 Billable/Specific Code Manifestation Code
    Applicable To
    • Pyelonephritis
    • Tubulo-interstitial nephritis
    Code First
    Type 1 Excludes
    • diphtheritic pyelonephritis and tubulo-interstitial nephritis (A36.84)
    • pyelonephritis and tubulo-interstitial nephritis in candidiasis (B37.49)
    • pyelonephritis and tubulo-interstitial nephritis in cystinosis (E72.04)
    • pyelonephritis and tubulo-interstitial nephritis in salmonella infection (A02.25)
    • pyelonephritis and tubulo-interstitial nephritis in sarcoidosis (D86.84)
    • pyelonephritis and tubulo-interstitial nephritis in sicca syndrome [Sjogren's] (M35.04)
    • pyelonephritis and tubulo-interstitial nephritis in systemic lupus erythematosus (M32.15)
    • pyelonephritis and tubulo-interstitial nephritis in toxoplasmosis (B58.83)
    • renal tubular degeneration in diabetes (E08-E13 with .29)
    • syphilitic pyelonephritis and tubulo-interstitial nephritis (A52.75)
    ICD-10-CM Diagnosis Code M36.1

    Arthropathy in neoplastic disease

      2016 2017 2018 2019 2020 2021 Billable/Specific Code Manifestation Code
    Code First
    • underlying neoplasm, such as:
    • leukemia (C91-C95)
    • malignant histiocytosis (C96.A)
    • multiple myeloma (C90.0)

Diagnosis Index entries containing back-references to C90.0:
  • Arthritis, arthritic (acute) (chronic) (nonpyogenic) (subacute) M19.90
    ICD-10-CM Diagnosis Code M19.90

    Unspecified osteoarthritis, unspecified site

      2016 2017 2018 2019 2020 2021 Billable/Specific Code
    Applicable To
    • Arthrosis NOS
    • Arthritis NOS
    • Osteoarthritis NOS
    • in (due to)
      • multiple myelomatosis C90.0-
      • myelomatosis C90.0- (multiple)
  • Arthropathy M12.9
    - see also Arthritis
    ICD-10-CM Diagnosis Code M12.9

    Arthropathy, unspecified

      2016 2017 2018 2019 2020 2021 Billable/Specific Code
    • in (due to)
      • multiple myeloma C90.0-
  • Disorder (of) - see also Disease
    • glomerular (in) N05.9
      ICD-10-CM Diagnosis Code N05.9

      Unspecified nephritic syndrome with unspecified morphologic changes

        2016 2017 2018 2019 2020 2021 Billable/Specific Code
      • multiple myeloma C90.0-
    • tubulo-interstitial (in)
      • multiple myeloma C90.0-
  • Glomerulonephritis N05.9
    - see also Nephritis
    ICD-10-CM Diagnosis Code N05.9

    Unspecified nephritic syndrome with unspecified morphologic changes

      2016 2017 2018 2019 2020 2021 Billable/Specific Code
    • in (due to)
      • multiple myeloma C90.0-
  • Kahler's disease C90.0-
  • Myeloma (multiple) C90.0-
    • monostotic C90.3
      ICD-10-CM Diagnosis Code C90.3

      Solitary plasmacytoma

        2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
      Applicable To
      • Localized malignant plasma cell tumor NOS
      • Plasmacytoma NOS
      • Solitary myeloma
      • plasma cell C90.0-
    • plasma cell C90.0-
  • Myelomatosis C90.0-
  • Plasmacytoma C90.3-
    ICD-10-CM Diagnosis Code C90.3-

    Solitary plasmacytoma

      2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
    Applicable To
    • Localized malignant plasma cell tumor NOS
    • Plasmacytoma NOS
    • Solitary myeloma
    • medullary C90.0-
  • Pyelonephritis - see also Nephritis, tubulo-interstitial
    • in (due to)
      • multiple myeloma C90.0-

ICD-10-CM Codes Adjacent To C90.0
C86.5 Angioimmunoblastic T-cell lymphoma
C86.6 Primary cutaneous CD30-positive T-cell proliferations
C88 Malignant immunoproliferative diseases and certain other B-cell lymphomas
C88.0 Waldenström macroglobulinemia
C88.2 Heavy chain disease
C88.3 Immunoproliferative small intestinal disease
C88.4 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]
C88.8 Other malignant immunoproliferative diseases
C88.9 Malignant immunoproliferative disease, unspecified
C90 Multiple myeloma and malignant plasma cell neoplasms
C90.0 Multiple myeloma
C90.00 …… not having achieved remission
C90.01 …… in remission
C90.02 …… in relapse
C90.1 Plasma cell leukemia
C90.10 …… not having achieved remission
C90.11 …… in remission
C90.12 …… in relapse
C90.2 Extramedullary plasmacytoma
C90.20 …… not having achieved remission
C90.21 …… in remission

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.